Danish pharmaceutical group Novo Nordisk and U.S. group Hims & Hers Health have announced a collaboration as part of a strategic shift to expand access to weight loss treatments.
CNBC’s Charlotte Reed speaks to Novo Nordisk Mike Doustdar about a new collaboration with U.S. firm Hims & Hers Health to improve access to GLP-1 weight loss treatments in America and gloablly.